Recursion Pharmaceuticals, Inc. (RXRX) Return on equity 2021–2025
Recursion Pharmaceuticals, Inc. (RXRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-57.0%FY2025 · since FY2021: -34.3% → -57.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -57.0% | -12.2 pp |
| FY2024 | -44.8% | +26.0 pp |
| FY2023 | -70.8% | -21.5 pp |
| FY2022 | -49.3% | -14.9 pp |
| FY2021 | -34.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More RXRX financial trends
RXRX RevenueRXRX Net incomeRXRX Net marginRXRX Gross profitRXRX Gross marginRXRX Operating incomeRXRX Operating marginRXRX Operating cash flowRXRX Free cash flowRXRX Capital expendituresRXRX Stock buybacksRXRX Dividends paidRXRX Total assetsRXRX Total liabilitiesRXRX Shareholders’ equityRXRX overview →